Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Recurrent Breast Cancer
Interventions: DRUG: Taselisib|DRUG: Trastuzumab emtansine|DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: Paclitaxel
Sponsor: Otto Metzger, MD
Collaborators: Genentech, Inc.